CHICAGO — March 11, 2026
Tempus AI, Inc., a technology company focused on advancing precision medicine through artificial intelligence and genomic data, announced the publication of a new research study demonstrating the critical role of advanced comprehensive genomic profiling (CGP) in identifying clinically actionable findings for cancer patients. The study, published in JCO Precision Oncology, highlights how advanced genomic testing capabilities—including tumor-normal matched sequencing, RNA sequencing, and liquid biopsy reflex testing—can significantly expand treatment options for patients in community oncology settings. The research was conducted in collaboration with The Oncology Institute (TOI) and reveals that many clinically actionable findings are missed when using standard in-network genomic tests that lack these advanced features.
Advanced Genomic Profiling Unlocks New Treatment Opportunities
The study underscores the growing importance of comprehensive genomic profiling in modern oncology, particularly as physicians increasingly rely on molecular insights to guide targeted cancer therapies. Leading organizations such as the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend genomic testing to help determine optimal treatment pathways for cancer patients. However, existing clinical guidelines often do not clearly define which specific testing features should be included in genomic panels.
According to the research, advanced genomic profiling technologies can identify clinically actionable mutations that would otherwise remain undetected with standard testing approaches. These advanced features include tumor-normal matched sequencing, which compares a patient’s tumor DNA with normal DNA to identify somatic mutations more accurately, as well as RNA sequencing, which provides insights into gene expression changes that may influence treatment response.
Another key component highlighted in the study is liquid biopsy reflex testing, a method that analyzes circulating tumor DNA in blood samples. This approach allows clinicians to detect cancer-related mutations when tissue samples are insufficient or unavailable, providing a powerful complementary tool for comprehensive genomic analysis.
Advertisement
Study Reveals Actionable Findings Missed by Standard Testing
The findings demonstrate that 12 percent of patients across the study cohorts—approximately one in eight individuals—had potentially actionable genomic findings that were identified exclusively through advanced Tempus testing features. These findings were linked to approved therapies or clinical trial opportunities that would not have been detected through more limited genomic testing methods.
This result highlights the significant clinical impact of more comprehensive genomic profiling in real-world oncology settings. By integrating tumor-normal sequencing, RNA analysis, and liquid biopsy technologies, physicians can gain a more complete understanding of the molecular drivers of a patient’s cancer, allowing them to select targeted therapies that may improve treatment outcomes.
Researchers involved in the study emphasized that genomic testing is not simply about the number of genes included in a panel but rather about the depth and sophistication of the testing methodology. Advanced genomic features can reveal complex molecular alterations that are essential for guiding personalized treatment strategies.
The study also demonstrates the growing role of AI-enabled genomic platforms, such as those developed by Tempus, in helping clinicians interpret complex molecular data and translate it into actionable clinical insights. By combining artificial intelligence, large-scale genomic datasets, and multimodal clinical data, such platforms are helping physicians identify the most effective therapies for individual patients.
AI and Data Integration Drive the Future of Precision Oncology
Tempus continues to position itself at the forefront of AI-driven precision medicine, leveraging one of the world’s largest libraries of multimodal healthcare data, including genomic, clinical, and molecular datasets. The company’s technology platform integrates these data sources into a comprehensive operating system that enables clinicians to analyze patient data more effectively and make informed treatment decisions.
Through the use of AI-powered analytics and genomic profiling technologies, Tempus aims to ensure that each cancer patient benefits from insights derived from previous cases and accumulated medical data. The company’s approach allows physicians to access data-driven recommendations that continuously improve as more genomic and clinical information becomes available.
As oncology research advances, experts believe that comprehensive genomic profiling will become an essential component of cancer care, enabling clinicians to match patients with precision therapies, targeted treatments, and innovative clinical trials. Studies such as this highlight the importance of adopting advanced genomic technologies that capture the full complexity of cancer biology.
By demonstrating how advanced genomic features can uncover clinically actionable findings that standard tests miss, the Tempus study reinforces the value of next-generation genomic profiling platforms in expanding treatment possibilities for cancer patients. As precision medicine continues to evolve, integrating AI, genomics, and large-scale data analytics may play a transformative role in improving outcomes for individuals living with cancer.
z
Source: Tempus AI press release
